News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
AOL.com Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Jennifer Lee, EVP of Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM), sold approximately $8.9 million worth of common stock after exercising options for about $997,036. The sale was executed under a Rule 10b5-1 trading plan as the stock trades near its 52-week high and is considered overvalued …
Jennifer Kayden Lee, EVP of Rhythm Pharmaceuticals (RYTM), exercised 56,601 stock options at prices of $24.29 and $6.80, and subsequently sold 75,834 common shares at $117.3818 per share. These transactions, valued at approximately $8.90 million gross proceeds from sales and $997K in exercise costs, …
Algorhythm Holdings (NASDAQ: MICS) reported a net loss of $4.1 million for Q2 2026, or $0.25 per share, an increase from the $0.24 loss per share in Q2 2025, due to heavy investment in growth. Despite the widening loss, revenue surged by 161% to …
iRhythm Holdings,Inc. IRTC recently announced that it will acquire Vital Connect, Inc., a leader in wearable biosensor technology and ambulatory cardiac monitoring. The transaction is expected to expand iRhythm's addressable market and accelerate its evolution from ambulatory cardiac monitoring into a broader cardiac monitoring …
Algorhythm Holdings Inc has released its earnings summary for the quarter that ended on June 30. The article, sourced from Reuters and republished on TradingView News, provides an overview of the company's financial performance during this period. Readers can access the full report and …
Algorhythm Holdings (NASDAQ: RIME) reported Q2 2026 EPS of $(0.25), significantly beating the $(0.36) analyst consensus. Revenue reached $3.005 million, exceeding estimates by 0.17% and representing a 161% year-over-year increase, driven by strategic expansions in North America and India. Despite top-line growth, the company's …
Algorhythm Holdings, Inc. (RIME) reported its Q2 2026 financial results, with revenue increasing to $3.01 million and a net loss of $(3.83) million, resulting in a diluted loss per share of $(0.25). This growth was largely due to the acquisition of SMCB and the …
Rhythm Pharmaceuticals received expanded UK MHRA authorization and orphan drug designation for IMCIVREE to treat hypothalamic obesity, broadening its market in the UK. While this strengthens the rare-disease thesis for the drug, the company continues to operate at a significant loss, underscoring ongoing funding …
An investor in Rhythm Pharmaceuticals (NASDAQ: RYTM) has filed a notice to sell 5,079 shares of common stock, valued at $597,290.40. The sale is planned through Morgan Stanley Smith Barney LLC on or after August 13, 2026, on NASDAQ. These shares originate from stock …
An insider at Rhythm Pharmaceuticals (RYTM) has filed a Form 144 indicating a proposed sale of 75,834 common shares through Morgan Stanley Smith Barney LLC. This total includes 56,601 shares from stock option exercises dated August 13, 2026, and 19,233 shares from Restricted Stock …
Rhythm Pharmaceuticals (RYTM) has announced a planned sale of 57,000 shares of its common stock through Morgan Stanley Smith Barney LLC Executive Financial Services. The total aggregate market value of these shares is $6,432,165.00, with the sale scheduled for August 12, 2026. This transaction …
Rhythm Pharmaceuticals (NASDAQ: RYTM) stock is trading higher due to the UK's expanded marketing authorization for its drug, Imcivree (setmelanotide). The approval now includes treatment for obesity and hunger control in adults and children with acquired hypothalamic obesity. Analysts have reiterated Buy ratings and …
Bank of America Corp DE reduced its stake in iRhythm Technologies by 41.7% in Q1, selling over 309,000 shares but still holding shares worth $51 million. Despite this reduction, iRhythm reported strong Q1 results with revenue up 20.1% year-over-year and earnings exceeding analyst expectations. …
The Top 5 Analyst Questions From iRhythm's Q2 Earnings Call iRhythm's second quarter results were met with a strong positive market reaction, reflecting the company's ability to deliver both robust revenue growth and significant margin improvement. Management attributed this performance to sustained demand for …
Analysts have given iRhythm Technologies (NASDAQ:IRTC) an average recommendation of "Moderate Buy," with a consensus price target of $179.93. The company recently reported strong quarterly earnings, beating expectations with an EPS of $0.58 and revenue of $224.17 million, a 20.1% year-over-year increase. Institutional investors, …
Algorhythm Holdings, Inc. (NASDAQ: RIME), a leading AI-powered logistics solutions provider, announced it will release its second-quarter financial results for the period ending June 30, 2026, on Friday, August 14, 2026. The company, through its subsidiary SemiCab, focuses on optimizing logistics for major retailers …
A Rhythm Pharmaceuticals insider, Pamela Cramer, has filed a Form 144 detailing planned sales of company common stock through a 10b5-1 plan via Morgan Stanley Smith Barney LLC. The filing includes shares from stock option exercises and restricted stock units, alongside a previous sale …
[Doctor and patient in conversation, looking at digital tablet] Solskin * iRhythm (IRTC [https://seekingalpha.com/symbol/IRTC]) ticked lower by 2% amid comments from Spruce Point Research. * iRhythm (IRTC [https://seekingalpha.com/symbol/IRTC]) didn't immediately respond to Seeking Alpha's email request for comment. * Spruce Point first issued a …
Algorhythm Holdings is scheduled to release its second-quarter 2026 financial results on August 14, 2026. This news brief was generated by Public Technologies using AI and is based on original content published by Algorhythm Holdings Inc. via GlobeNewswire. The information is for informational purposes …
Algorhythm Holdings (NASDAQ:RIME) announced it will release its financial results for the second quarter ended June 30, 2026, on Friday, August 14, 2026. The AI-powered logistics solutions provider shared this information from Fort Lauderdale, Florida. Prior comparable earnings-date events for the company have averaged …
Rhythm Pharmaceuticals, Inc. -- MHRA grants authorization for patients 4 years of age and above with acquired hypothalamic obesity due to hypothalamic injury or impairment -- BOSTON, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused …
Quantinno Capital Management LP significantly increased its stake in iRhythm Technologies (NASDAQ:IRTC) by 1,172.8% in the first quarter, now owning 18,621 shares valued at approximately $2.2 million. The company reported strong financial results, with quarterly revenue up 20.1% year over year to $224.17 million …
This article provides a technical analysis of Irhythm Technologies Inc. (NASDAQ: IRTC), detailing institutional trading strategies based on AI models. It identifies strong near- and mid-term sentiment but a weak long-term outlook, with key support and resistance levels. The analysis also highlights a significant …
Rhythm Pharmaceuticals (NASDAQ:RYTM) has received a "Moderate Buy" consensus recommendation from brokerages, with 15 out of 18 analysts rating the stock as a buy. The average 12-month price target is $142.44, exceeding the current share price of $115.48. The company reported strong quarterly revenue …
This article details an SEC Form 144 filing by RHYTHM PHARMACEUTICALS, INC. (RYTM) on August 10, 2026. The filing indicates a proposed sale of 3,520 common shares with an aggregate market value of $407,017.60, acquired through the exercise of stock options on the same …
Why iRhythm (IRTC) Stock Is Trading Up Today What Happened? Shares of medical technology company iRhythm Technologies (NASDAQ:IRTC) jumped 2% in the afternoon session after the company reported strong second-quarter financial results that surpassed expectations and raised its full-year guidance. The cardiac monitoring company …
Search by ticker symbol or company name and select a result to open its chart.